The National Lung Screening Trial (NLST) was a randomized controlled trial to determine whether screening for lung cancer with low-dose helical computed tomography (CT) reduces mortality from lung cancer in high-risk individuals relative to screening with chest radiography. Approximately 54,000 participants were enrolled between August 2002 and April 2004. Data collection has ended, and information is complete through December 31, 2009. NLST has the ClinicalTrials.gov registration number NCT00047385.
This website enables users to request NLST datasets and images, learn about NLST, and search a database of research projects and publications. To obtain NLST datasets, CT images, and/or pathology images, submit a request through this website. The datasets are comprehensive; they include data on participant characteristics, screening exam results, diagnostic procedures, lung cancer, and mortality. Images from over 75,000 CT screening exams are available. Over 1,200 pathology images from a subset of NLST lung cancer patients (~500 of over 2,000 patients) may be viewed.
This website is organized into several sections as follows.
- Learn about NLST
This describes the trial, explaining how and what data were collected. The main findings of the trial can be found here.
This page has detailed documentation of the NLST datasets available on this website, including data dictionaries.
- Approved Projects
Search through approved projects that used NLST data.
Search through published articles on NLST data.
Learn about NLST CT Images
Learn how to access the available NLST datasets and images.
- Submit a project proposal.
- Brief review by NCI.
- Complete a Data Transfer Agreement.
- Receive access to datasets and images.
- Contact Us
If you have any questions about the data or access to it, please contact us.
NLST Resources from Other Web Sites
Note that NLST was administered by two separate groups: the Lung Screening Study group (LSS), and the American College of Radiology Imaging Network (ACRIN).
- (For CT and Pathology images, submit a request through this website. See Images page for more information.)
- A tissue resource (microarrays and dna cores) for lung cancer was created from tissue resected as part of lung cancer diagnosis and treatment. These specimens are available through the PLCO Etiologic and Early Marker Studies Program (EEMS). More information about the materials available and protocol of collection is available in the Biospecimens Collected section, and to learn about the approval process for acquisition see the PLCO EEMS Application page section.
- ACRIN collected biospecimens, including blood, urine, and sputum collected at the screening exams, and tissue from participants diagnosed with lung cancer. Availability of ACRIN biospecimens can be inquired by contacting ACRIN.
- Availability of additional ACRIN can be inquired by contacting ACRIN.